Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers.
The identification of tumor-associated/-specific antigens and an increased understanding of the ways in which antigens are processed and presented has led to a revived interest in cancer vaccines as a therapeutic strategy. BLP25 liposome (L-BLP25) vaccine is a cancer vaccine that targets the exposed core peptide of the MUC1 tumor-associated antigen. Studies in advanced-stage non-small cell lung cancer demonstrate that L-BLP25 vaccine has the potential to extend the survival of patients with Stage IIIB locoregional non-small cell lung cancer and maintain quality of life for longer. L-BLP25 vaccine also shows promise for prostate cancer patients, having the potential to prolong prostate-specific antigen doubling time in men with biochemical failure post prostatectomy. These clinically meaningful results with a relatively nontoxic therapeutic vaccine are very encouraging and suggest potential for L-BLP25 to fulfill an unmet medical need.
North
Scott
S
Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta T6G 1Z2, Canada. scottnor@cancerboard.ab.ca
Butts
Charles
C
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D008081:Liposomes; D008175:Lung Neoplasms / Q000276:immunology / Q000517:prevention & control*; D008297:Male; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control*
D019496:Cancer Vaccines; D008081:Liposomes